|Application ||WB, IF|
|Calculated MW||51386 Da|
|Other Names||Keratin, type II cytoskeletal 7, Cytokeratin-7, CK-7, Keratin-7, K7, Sarcolectin, Type-II keratin Kb7, KRT7, SCL|
|Target/Specificity||A synthetic peptide corresponding to residues near the C-terminus of human CK-7 was used as an immunogen.|
|Format||50 mM Tris-Glycine (pH 7.4), 0.15 M NaCl, 40% Glycerol, 0.01% sodium azide and 0.05% BSA.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||Cytokeratin-7 Antibody (C-term) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Blocks interferon-dependent interphase and stimulates DNA synthesis in cells. Involved in the translational regulation of the human papillomavirus type 16 E7 mRNA (HPV16 E7).|
|Tissue Location||Expressed in cultured epidermal, bronchial and mesothelial cells but absent in colon, ectocervix and liver Observed throughout the glandular cells in the junction between stomach and esophagus but is absent in the esophagus|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Cytokeratins are cytoplasmic intermediate filament proteins expressed by epithelial cells. Keratin 7 (CK7) is expressed in a wide range of epithelial structures in humans. The expression pattern in mice is similar to the reported human distribution, with substantial expression observed in lung, bladder, mesothelium, hair follicle, and ductal structures (1). Protein expression levels of CK7 appear significantly higher in chromophobe RCC compared to oncocytoma (p < 0.001). Studies provide further evidence that CK7 and parvalbumin immunostains may be useful in differentiating oncocytoma from chromophobe RCC in problematic cases (2). Also, the pattern of immunohistochemical expression of CK 7 along with CK 20 is commonly used to assess possible primary sites of metastatic carcinomas (3).
1. Smith FJ, et al. Biochem Biophys Res Commun. 297(4):818-27, 2002.
2. Adley BP, et al. Anal Quant Cytol Histol 28(4):228-36, 2006
3. Coons SW, et al. Endocr Pathol 16(3):201-10, 2005.
If you have any additional inquiries please email technical services at email@example.com.